Clinical trials: Anticholinergics
Chronic Obstructive Pulmonary Disease
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
This study is a post-authorization commitment to the European Medicines Agency (EMA). The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the…
- Trial name
- NCT02371629
- Testing
- NVA237, Salbutamol
- Where
- 81 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 776 people
- Sponsor
- Novartis Pharmaceuticals
Anticholinergic Delirium, Clozapine Poisoning
Rivastigmine as an Antidote for Clozapine-induced Central Nervous System Depression and Delirium
This study aims to evaluate the clinical efficacy and safety of rivastigmine in reversing the full spectrum of anticholinergic delirium including hypoactive delirium which is presented with CNS depression and hyperactive or…
- Conditions
- Anticholinergic Delirium, Clozapine Poisoning, Antipsychotic Toxicity, CNS Depression
- Trial name
- NCT07545382
- Testing
- Rivastigmine
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Overactive Bladder Associated With HTLV-1
A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder
It's a double blind, placebo controlled study to assess the efficacy of Propantheline Bromide to treat overactive bladder (OAB) in HTLV 1 infected patients.
- Trial name
- NCT01640002
- Testing
- Propantheline Bromide
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Subjects Undergoing Flexible Bronchoscopy
A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy
No study has examined the role of inhaled glycopyrrolate on mucus secretion. We hypothesize that nebulized glycopyrrolate will improve bronchoscopy procedure by effectively suppressing airway mucus secretion, thereby decreasing…
- Trial name
- NAFCOF (NCT06376942)
- Testing
- Glycopyrronium, Ipratropium, Saline
- Where
- India
- Volunteers
- 1,050 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work…
- Trial name
- NCT00783003
- Testing
- GSK233705 and GW642444, GW642444, GSK233705
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Urinary Incontinence, Bladder Dysfunction
Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients
Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke
- Trial name
- NCT00713921
- Testing
- Fesoterodine Oral Product
- Where
- United States
- Sponsor
- Saint Thomas Health
Anticholinergic Syndrome, Anticholinergic Adverse Reaction
The Effects Of Anticholinergic Burden On Daily Living Activities In Elderly Patients
The anticholinergic burden was calculated based on the medications that the patients had used for more than 10 days. Short-term medications used by patients were not evaluated.
- Conditions
- Anticholinergic Syndrome, Anticholinergic Adverse Reaction, Antispasmodic Adverse Reaction, Antiarrhythmic Drug Adverse Reaction
- Trial name
- NCT05902676
- Volunteers
- 180 people
- Sponsor
- Izmir Ataturk Training and Research Hospital
Healthy
Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products
The purpose of this study is to compare the absorption of two different inhalation products with the reference product in healthy volunteers.
- Trial name
- NCT02676297
- Testing
- tiotropium
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Solventum US LLC
Urinary Incontinence, Urgency Urinary
Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Urinary incontinence (UI) is a very common condition affecting women of all ages. The objective of this pilot study is to better understand the urinary microbiome and associated inflammatory markers in blood and urine in women…
- Trial name
- NCT04090190
- Testing
- Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Chronic Spinal Cord Injury, Neurogenic Bladder
Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
The purpose of this study is to determine the efficacy of home transcutaneous tibial nerve stimulation (TTNS) in spinal cord injury(SCI) and to determine the impact on quality of life using TTNS at home
- Trial name
- TTNS-RCT (NCT04074616)
- Testing
- High Dose, Low dose
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pulmonary Disease, Chronic Obstructive
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation…
- Trial name
- DB2113361 (NCT01313637)
- Testing
- GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg
- Where
- 157 sites in United States, Belgium and 12 more
- Volunteers
- 1,493 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease, Neurogenic Bladder
Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
The basic nerve deficit of Parkinson's disease (PD) leads to lower urinary tract symptoms of frequency, urgency and urge urinary incontinence. Lower urinary tract symptoms tend to occur at more advanced stages of PD.
- Conditions
- Parkinson's Disease, Neurogenic Bladder, Urinary Incontinence, Clostridium Botulinum Toxin Adverse Reaction
- Trial name
- NCT01421719
- Testing
- Cystoscopic injection of Botox into the urinary bladder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment
Efficacy of 200 IU OnabotulinumtoxinA in Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment
This study aimed to assess the efficacy and safety of onabotulinumtoxinA (botulinum toxin type A) in patients with idiopathic overactive bladder (OAB) and urinary incontinence who had previously failed to respond to…
- Trial name
- NCT06408051
- Testing
- Injection of onabotulinumtoxinA into the bladder wall
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hisar Intercontinental Hospital
Anticholinergic Toxicity
Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium
Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors.
- Trial name
- RIVA-AP (NCT06399679)
- Testing
- Rivastigmine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Hyperhidrosis, Oxybutynin
Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?
The TODAY trial is a study to evaluate the efficacy and safety of topical oxybutynin deodorant for use in patients with axillary hyperhidrosis.
- Conditions
- Hyperhidrosis, Oxybutynin, Sweat Gland Diseases, Skin Diseases
- Trial name
- TODAY (NCT05102396)
- Testing
- Topical oxybutynin spray, Oral oxybutynin
- Where
- Brazil
- Volunteers
- 17 people
- Sponsor
- Samantha Rodrigues Camargo Neves de Moura
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
To obtain further information on the prescribing pattern and therapeutic long term value in patients suffering from moderate or severs Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238184
- Testing
- Atrovent®, Ventilat®
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Overactive Bladder (OAB)
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.
- Trial name
- NCT02294396
- Testing
- Mirabegron tablet, Solifenacin tablet, Propiverine tablet
- Where
- 7 sites in Japan
- Volunteers
- 649 people
- Sponsor
- Astellas Pharma Inc
Parkinson's Disease
Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o.), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations…
- Trial name
- NCT01187966
- Testing
- Safinamide
- Volunteers
- 669 people
- Sponsor
- Newron Pharmaceuticals SPA
Overactive Bladder (OAB)
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.
- Trial name
- NCT03903094
- Testing
- Non-Interventional
- Where
- 2 sites in Australia, South Korea
- Volunteers
- 6,295,279 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Epilepsy, Seizures
Pharmacological Modulation of Brain Oscillations in Memory Processing
The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity.
- Conditions
- Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorders
- Trial name
- NCT05594017
- Testing
- Scopolamine (0.4mg)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center